カジノ シークレット 入金 Releases

Mar. 6, 2026

カジノ シークレット 入金

Notice Regarding a Subsidiary Obtaining Manufacturing and Marketing Authorization for iPS Cell-Derived Product "AMCHEPRY^®" for the Treatment of Parkinson's Disease

Mar. 2, 2026

カジノ シークレット 入金

Notice Regarding the Filing of a Shelf Registration for the Issuance of New Shares by a Subsidiary

Feb. 3, 2026

カジノ シークレット 入金

Announcement of Extraordinary Loss in Non-consolidated Financial Statements

Feb. 3, 2026

カジノ シークレット 入金

Notice Concerning Share of Loss of Investments Accounted for Using the Equity Method

Feb. 3, 2026

カジノ シークレット 入金

カジノ シークレット 入金 Chemical Announces Revisions to Its Financial Forecast and Projected Dividend for the Full Year Ending March 31, 2026

Feb. 3, 2026

カジノ シークレット 入金

Summary of Consolidated Financial Results for Thカジノ シークレット 入金d Quarter Fiscal Year 2025

Jan. 16, 2026

カジノ シークレット 入金

(Progress of Disclosed Matters) Notice Regarding Determination of Share Exchange Ratio in Simplified Share Exchange between カジノ シークレット 入金 Chemical Co., Ltd. and Tanaka Chemical Corporation